Routine characterization of biomarkers in non-small cell lung carcinoma: how much is enough?
Read
6296
Timeswas read the article
2409
Total PDF
3887
Total HTML
Share statistics
array:20 [ "pii" => "X0873215915188369" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2015.04.001" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:109-10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3162 "formatos" => array:3 [ "EPUB" => 238 "HTML" => 1987 "PDF" => 937 ] ] "itemSiguiente" => array:16 [ "pii" => "X0873215915188377" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2015.04.002" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:111-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3995 "formatos" => array:3 [ "EPUB" => 236 "HTML" => 2654 "PDF" => 1105 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Omalizumab: a treatment for severe asthma in real life?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "111" "paginaFinal" => "112" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Anaïs Briquet, Pascal Chanez" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Anaïs" "apellidos" => "Briquet" ] 1 => array:2 [ "nombre" => "Pascal" "apellidos" => "Chanez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188377?idApp=UINPBA00004E" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188377/v0_201604141146/en/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S217351151500038X" "issn" => "21735115" "doi" => "10.1016/j.rppnen.2014.09.009" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "1039" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:113-25" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1885 "formatos" => array:3 [ "EPUB" => 201 "HTML" => 1174 "PDF" => 510 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "113" "paginaFinal" => "125" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0030" "etiqueta" => "Figure 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 586 "Ancho" => 995 "Tamanyo" => 57900 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Case 7: FISH positive for EGFR/chromosome 7 centromere. Gene high polysomy; <span class="elsevierStyleItalic">EGFR –</span> red signal, chromosome 7-green. 1000×.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Vitor Sousa, Carolina Rodrigues, Maria Silva, Ana Maria Alarcão, Lina Carvalho" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Vitor" "apellidos" => "Sousa" ] 1 => array:2 [ "nombre" => "Carolina" "apellidos" => "Rodrigues" ] 2 => array:2 [ "nombre" => "Maria" "apellidos" => "Silva" ] 3 => array:2 [ "nombre" => "Ana Maria" "apellidos" => "Alarcão" ] 4 => array:2 [ "nombre" => "Lina" "apellidos" => "Carvalho" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217351151500038X?idApp=UINPBA00004E" "url" => "/21735115/0000002100000003/v2_201505070217/S217351151500038X/v2_201505070217/en/main.assets" ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Routine characterization of biomarkers in non-small cell lung carcinoma: how much is enough?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "109" "paginaFinal" => "110" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "José Carlos Machado" "autores" => array:1 [ 0 => array:4 [ "nombre" => "José Carlos" "apellidos" => "Machado" "email" => array:1 [ 0 => "joseclm@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Department of Pathology and Oncology, Medical Faculty of Porto, Porto, Portugal" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "textoCompleto" => "<p class="elsevierStylePara">In recent years there was an extraordinary development in targeted therapies for cancer. This development was quickly followed by the realization that successful application of these therapies is highly dependent on the identification and routine use of predictive biomarkers of therapy response. In this context, the fine characterization of tumours, both at the molecular and histopathological levels, might provide fundamental insight. In the study by Sousa et al.,<a href="#bib1" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a> published in the current issue of the Portuguese Journal of Pulmonology, the authors show adenocarcinomas of the lung are highly heterogeneous from the histopathological standpoint and show different patterns of expression of immunohistochemical and genetic biomarkers. In their study the authors used a set of 10 immunohistochemical biomarkers and 3 genetic biomarkers. The authors further reinforce the need to carefully identify lung adenocarcinoma histological patterns with putative implications in diagnosis and pathogenesis understanding. Unfortunately, the study does not include data on the clinical follow-up of the patients precluding the analysis of the predictive value of the data presented. Nevertheless, the publication of this study may constitute a good opportunity to discuss the clinical impact of routine characterization of biomarkers in non-small cell lung carcinoma.</p><p class="elsevierStylePara">The diagnosis of lung cancer involves a variety of approaches ranging from pathology to medical imaging and molecular biology. As our understanding of the disease grows, and new knowledge is translated into clinically relevant procedures, there is an increasing pressure on diagnostic turnaround times and relevant sample material for the increased number of companion tests prior to decision-to-treat. Advanced lung cancer diagnostics are a showcase for this challenge; biological material for diagnostics procedures is often limited (cytology and biopsy material), and timely responses are needed for optimal therapeutic decisions. In this cancer model, tumour samples are necessary for routine pathology evaluation combined with advanced molecular biology analysis.</p><p class="elsevierStylePara">The diagnosis and histological classification of lung cancer into its major subtypes - small cell lung carcinoma, adenocarcinoma and squamous carcinoma - relies on morphological characterization and on the use of differentiation biomarkers. Although several markers are available for routine diagnosis, the immunohistochemical expression of TTF1 and p63 are currently markers of choice to put forth differential diagnosis between squamous carcinoma and adenocarcinoma of the lung. Expression of TTF1 favours the diagnosis of adenocarcinoma, whereas expression of p63 favours diagnosis of squamous carcinoma.</p><p class="elsevierStylePara">The addition of tyrosine kinase inhibitors into the therapeutic arsenal of non-small cell lung carcinoma, brought into routine clinical practice the analysis of mutations in the <span class="elsevierStyleItalic">EGFR</span> and <span class="elsevierStyleItalic">KRAS</span> genes, and the detection of chromosomal translocations involving the <span class="elsevierStyleItalic">ALK</span> and <span class="elsevierStyleItalic">ROS1</span> genes. Specific activating mutations in exons 18, 19, 20 and 21 of the <span class="elsevierStyleItalic">EGFR</span> gene allow selection of 10-20% of patients for treatment with the EGFR inhibitors gefitinib™ or erlotinib™. In contrast, patients with other <span class="elsevierStyleItalic">EGFR</span> mutations, namely insertions and deletions in exon 20, and mutations in the <span class="elsevierStyleItalic">KRAS</span> gene, are not likely to respond to the same EGFR inhibitors, and as such should receive alternative treatment. In addition, 3-5% of patients not eligible for EGFR-inhibitor treatment may still benefit from treatment with ALK-inhibitor crizotinib™ as long as they can be confirmed to carry chromosomal translocations involving the <span class="elsevierStyleItalic">ALK</span> or <span class="elsevierStyleItalic">ROS1</span> genes.</p><p class="elsevierStylePara">Currently, lack of integration between molecular assays, requires all the above described mutation and chromosomal translocations to be analysed sequentially in multiple assays. Each step demands its own biological aliquot for analysis and has its own turnaround time, challenging both sample requirement and laboratory diagnostics turnaround time. Typically, the biological material will be used first for histopathology analysis, which may include the study of protein markers such as TTF1 and p63 using immunohistochemistry (IHC). This step will typically take 5-10 working days. If diagnosis of non-small cell lung carcinoma is confirmed (80-85% of the cases), first-line therapy with EGFR inhibitors should be considered, especially for adenocarcinomas. The second step will therefore include mutation screening for the <span class="elsevierStyleItalic">EGFR</span> gene alone or in conjunction with the <span class="elsevierStyleItalic">KRAS</span> gene. This step will typically take 5-10 working days. If not eligible for anti-EGFR therapy there will be further testing for <span class="elsevierStyleItalic">ALK</span> and <span class="elsevierStyleItalic">ROS1</span> translocations using fluorescence in-situ hybridization (FISH) alone, or a combination of IHC and FISH. This third step takes additional 5-10 working days. Altogether, this three-step testing strategy may take something between 15 and 30 working days, delaying timely oncology treatment initiation and incurring patient insecurity. Additional delays may occur if samples need to be transferred between laboratories.</p><p class="elsevierStylePara">While we all eagerly await technological developments that allow for single-assay methods/devices coping with the current challenges of minimizing both the need for analytical biological material and turnaround time, there is a pressing need to prioritize the type and number of companion tests in lung cancer diagnosis. In that respect, current recommendations are very straightforward: as long as lung cancer diagnosis has been confirmed, all available biological material shall be prioritized for the analysis of molecular biomarkers with predictive value to therapy response which, at the time of this writing, include and are limited to <span class="elsevierStyleItalic">EGFR</span> and <span class="elsevierStyleItalic">KRAS</span> mutations, and <span class="elsevierStyleItalic">ALK</span> and <span class="elsevierStyleItalic">ROS1</span> translocations. International organizations, such as the CAP/IASLC/AMP, clearly state physicians should order predictive testing at the time of diagnosis for patients with advanced stage lung adenocarcinoma, regardless of their clinical history. That is how much is enough.</p>" "pdfFichero" => "320v21n03a90418836pdf001.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:1 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. Rev Port Pneumol. 2015. http://dx.doi.org/10.1016/j.rppnen.2014.09.009." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Sousa V" 1 => "Rodrigues C" 2 => "Silva M" 3 => "Alarcão AM" 4 => "Carvalho L." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Rev Port Pneumol. " "fecha" => "2015" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188369/v0_201604141146/en/main.assets" "Apartado" => array:4 [ "identificador" => "18132" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editoriais" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/08732159/0000002100000003/v0_201604141146/X0873215915188369/v0_201604141146/en/320v21n03a90418836pdf001.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188369?idApp=UINPBA00004E" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 9 | 15 |
| 2024 October | 32 | 30 | 62 |
| 2024 September | 27 | 23 | 50 |
| 2024 August | 38 | 33 | 71 |
| 2024 July | 52 | 29 | 81 |
| 2024 June | 41 | 22 | 63 |
| 2024 May | 28 | 34 | 62 |
| 2024 April | 41 | 27 | 68 |
| 2024 March | 28 | 24 | 52 |
| 2024 February | 33 | 19 | 52 |
| 2024 January | 25 | 19 | 44 |
| 2023 December | 25 | 29 | 54 |
| 2023 November | 30 | 28 | 58 |
| 2023 October | 19 | 34 | 53 |
| 2023 September | 25 | 29 | 54 |
| 2023 August | 19 | 21 | 40 |
| 2023 July | 20 | 25 | 45 |
| 2023 June | 18 | 15 | 33 |
| 2023 May | 32 | 21 | 53 |
| 2023 April | 24 | 15 | 39 |
| 2023 March | 30 | 14 | 44 |
| 2023 February | 39 | 25 | 64 |
| 2023 January | 20 | 16 | 36 |
| 2022 December | 24 | 21 | 45 |
| 2022 November | 36 | 34 | 70 |
| 2022 October | 39 | 23 | 62 |
| 2022 September | 26 | 37 | 63 |
| 2022 August | 32 | 36 | 68 |
| 2022 July | 27 | 47 | 74 |
| 2022 June | 20 | 30 | 50 |
| 2022 May | 37 | 39 | 76 |
| 2022 April | 31 | 34 | 65 |
| 2022 March | 34 | 36 | 70 |
| 2022 February | 33 | 35 | 68 |
| 2022 January | 29 | 39 | 68 |
| 2021 December | 33 | 27 | 60 |
| 2021 November | 22 | 33 | 55 |
| 2021 October | 31 | 50 | 81 |
| 2021 September | 24 | 31 | 55 |
| 2021 August | 16 | 24 | 40 |
| 2021 July | 21 | 16 | 37 |
| 2021 June | 16 | 34 | 50 |
| 2021 May | 28 | 30 | 58 |
| 2021 April | 73 | 51 | 124 |
| 2021 March | 61 | 11 | 72 |
| 2021 February | 46 | 20 | 66 |
| 2021 January | 21 | 10 | 31 |
| 2020 December | 28 | 10 | 38 |
| 2020 November | 37 | 17 | 54 |
| 2020 October | 26 | 16 | 42 |
| 2020 September | 41 | 29 | 70 |
| 2020 August | 46 | 25 | 71 |
| 2020 July | 65 | 18 | 83 |
| 2020 June | 55 | 16 | 71 |
| 2020 May | 46 | 23 | 69 |
| 2020 April | 43 | 10 | 53 |
| 2020 March | 64 | 14 | 78 |
| 2020 February | 91 | 24 | 115 |
| 2020 January | 71 | 18 | 89 |
| 2019 December | 52 | 19 | 71 |
| 2019 November | 49 | 18 | 67 |
| 2019 October | 63 | 18 | 81 |
| 2019 September | 46 | 17 | 63 |
| 2019 August | 49 | 10 | 59 |
| 2019 July | 54 | 14 | 68 |
| 2019 June | 50 | 8 | 58 |
| 2019 May | 46 | 15 | 61 |
| 2019 April | 45 | 23 | 68 |
| 2019 March | 100 | 11 | 111 |
| 2019 February | 79 | 7 | 86 |
| 2019 January | 104 | 22 | 126 |
| 2018 December | 52 | 6 | 58 |
| 2018 November | 13 | 1 | 14 |
| 2018 October | 13 | 11 | 24 |
| 2018 September | 18 | 11 | 29 |
| 2018 August | 30 | 22 | 52 |
| 2018 July | 40 | 20 | 60 |
| 2018 June | 32 | 15 | 47 |
| 2018 May | 36 | 28 | 64 |
| 2018 April | 52 | 23 | 75 |
| 2018 March | 50 | 21 | 71 |
| 2018 February | 20 | 10 | 30 |
| 2018 January | 22 | 17 | 39 |
| 2017 December | 32 | 33 | 65 |
| 2017 November | 19 | 11 | 30 |
| 2017 October | 10 | 17 | 27 |
| 2017 September | 23 | 15 | 38 |
| 2017 August | 18 | 14 | 32 |
| 2017 July | 17 | 10 | 27 |
| 2017 June | 26 | 22 | 48 |
| 2017 May | 24 | 17 | 41 |
| 2017 April | 14 | 7 | 21 |
| 2017 March | 8 | 7 | 15 |
| 2017 February | 6 | 6 | 12 |
| 2017 January | 9 | 5 | 14 |
| 2016 December | 10 | 10 | 20 |
| 2016 November | 6 | 5 | 11 |
| 2016 October | 2 | 1 | 3 |
| 2016 August | 3 | 3 | 6 |
| 2016 July | 2 | 9 | 11 |
| 2016 June | 2 | 0 | 2 |
| 2016 May | 7 | 7 | 14 |
| 2016 April | 8 | 2 | 10 |
| 2016 March | 18 | 10 | 28 |
| 2016 February | 14 | 15 | 29 |
| 2016 January | 16 | 12 | 28 |
| 2015 December | 28 | 15 | 43 |
| 2015 November | 13 | 8 | 21 |
| 2015 October | 22 | 18 | 40 |
| 2015 September | 26 | 23 | 49 |
| 2015 August | 54 | 41 | 95 |
| 2015 July | 36 | 25 | 61 |
| 2015 June | 74 | 39 | 113 |
| 2015 May | 200 | 126 | 326 |
Show all
